Amgen Says Tezspire Safety Profile Consistent With Approved Indications
AMGN•Reuters brief on Tezspire
Aug. 27 (Reuters) - Amgen Inc. AMGN.O:
- Tezspire® demonstrates positive Phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
- Amgen - Tezspire safety profile consistent with approved indications
Source text: ID:nPnPR3nda
Further company coverage: AMGN.O
